Objective: To investigate the efficacy and safety of 14 days' orally administered tolvaptan as adjunctive treatment for hepatic oedema in Japanese liver cirrhosis patients with insufficient response to conventional diuretics, with the option to increase dose in those who did not respond initially.
Introduction
Patients with liver cirrhosis and with hepatic oedema are at high risk of further complications of hepatic disease. [1] [2] [3] [4] Sodium dietary restriction and diuretic therapy are the primary treatment modalities for patients with hepatic oedema-manifested ascites. 5 Such diuretics often cause electrolyte imbalance before producing a sufficient amount of diuresis, however, [6] [7] [8] [9] which makes it difficult to make escalating dose adjustments for optimal diuretic effect in patients with hepatic dysfunction. 2, 10 Tolvaptan (Samsca TM ; Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan), a novel oral aquaretic agent, is an arginine vasopressin nonpeptide V 2 receptor antagonist, developed for the treatment of clinically significant hypervolaemic or euvolaemic hyponatraemia or less marked hyponatraemia in patients with heart failure, cirrhosis or syndrome of inappropriate antidiuretic hormone. [11] [12] [13] [14] [15] Tolvaptan is indicated for volume overload in heart failure at a daily dose of 15 mg/day, in Japan. [16] [17] [18] In addition to these indications, add-on therapy of tolvaptan to conventional diuretics is expected to be useful for the treatment of hepatic oedema, since tolvaptan induces the secretion of free water without sodium excretion (aquaresis). 19 In a pharmacokinetics/pharmacodynamics study, tolvaptan was shown to decrease body weight and ascites volume, and increase urine output, in a dose-dependent manner. 20 Additionally, a dose-finding study investigating the effect of a 7-day treatment with tolvaptan 7.5, 15, and 30 mg/day in hepatic oedema, determined that the optimal dose of tolvaptan was 7.5 mg/day, based on reductions in body weight and abdominal circumference. 21 Although doses of tolvaptan !15 mg/day have shown an aquaretic effect, 22 the effect of increasing the dose from 7.5 mg/day to 15 mg/day in patients who do not initially respond to 7.5 mg/day has not been investigated. Thus, the present study investigated whether a diuretic effect could be produced by increasing the dose to 15 mg/day for an additional 7 days, in patients who showed insufficient aquaretic effect after an initial 7day administration of tolvaptan 7.5 mg/day.
Patients and methods

Study population
This was a multicentre, single-arm, phase 3 study conducted between January and December 2010 at 39 study sites in Japan. Consecutive male or female patients with cirrhosis of the liver, who met all of the following criteria, were eligible for inclusion in the study: (i) age 20-80 years; (ii) persistent ascites despite conventional diuretic treatment; (iii) previous imaging diagnosis of liver cirrhosis; (iv) patients whose dose of conventional diuretics could not be increased due to adverse drug reactions or risk of adverse drug reactions, or where efficacy was insufficient; (v) patients who had been receiving one of the following combination therapies (loop diuretic and oral antialdosterone agent from !7 days prior to acquisition of informed consent): (a) loop diuretic dose equivalent to !40 mg/ day furosemide and !25 mg/day spironolactone or (b) loop diuretic dose equivalent to !20 mg/day furosemide and !50 mg/day spironolactone; (vi) inpatients at, or patients who could be admitted to, one of the study sites. Major exclusion criteria were: (i) hepatic encephalopathy (Inuyama classification 23 !grade II); (ii) history of cerebrovascular disorder; (iii) pregnancy; (iv) history of treatment with albumin products or blood products containing albumin;
(v) patients otherwise judged by the investigator to be inappropriate for inclusion in the study.
Written informed consent was obtained from all patients. The study protocol was approved by the institutional review board at each study site, and the study was conducted in compliance with the Declaration of Helsinki, 24 and according to the principles of Good Clinical Practice. This study was registered on Clinical Trials.gov (NCT01048788).
Study design
The study consisted of four periods: a 10-day screening period after obtaining informed consent; a 3-day pretreatment observation period (defined as baseline); a 14-day treatment period (the initial 7 days was defined as Treatment Period-I, and the subsequent 7 days as Treatment Period-II); a 7-day post-treatment observation period ( Figure 1 ). For all variables, data obtained immediately before the start of trial-drug administration were used as baseline data. The dose and regimen of conventional diuretics used prior to enrolment of this study were unchanged until the completion of the final assessment on the day following the final administration of tolvaptan. Patients in whom body weight before breakfast on the second and third days of the pretreatment observation period was stable (AE1.0 kg) were eligible for advancement to the treatment period, by investigator's judgement. Figure 1 . Design of a study to assess the efficacy and safety of tolvaptan in patients with hepatic oedemaassociated ascites refractory to conventional diuretic treatment. One-way arrow represents the patients with insufficient response after the initial 7 days' treatment with tolvaptan 7.5 mg/day (Treatment Period-I), who received an increased dose of tolvaptan 15 mg/day in Treatment Period-II.
During Treatment Period-I, all patients received 7.5 mg tolvaptan orally, once daily, after breakfast in combination with their fixed regimen of conventional diuretics (as only 15 mg and 30 mg tolvaptan tablets are licensed, 7.5 mg tablets made specifically for experimental use in clinical studies were administered). Patients who achieved a body-weight reduction of !1.0 kg by the end of Treatment Period-I continued to receive 7.5 mg/day tolvaptan during Treatment Period-II. Patients who did not achieve !1.0 kg reduction in body weight by the end of Treatment Period-I received 15 mg/ day tolvaptan in Treatment Period-II. Patients continued to receive 7.5 mg/day tolvaptan during Treatment Period-II if the investigator judged dose escalation to be inappropriate, based on the patient's volume expansion and any adverse events observed. Patients were hospitalized (for close monitoring) from the day before the pretreatment observational period until completion of the post-treatment observation period.
Efficacy evaluation
Improvement in hepatic oedema was assessed by the reduction in body weight as a marker for decrease in ascites volume, 1 and the primary endpoint was change in body weight from baseline. Body weight was measured every day throughout the treatment period, and abdominal circumference was measured on days 7 and 14, before breakfast and after urination. Patients who showed a body weight reduction of !1.0 kg in a week were defined as responders. The number and percentage of responders was calculated. Assessment of the response in Figure 2 . Flow chart indicating the recruitment and treatment of patients with hepatic oedema-associated ascites refractory to conventional diuretic treatment, included in a study to evaluate efficacy and safety of 7.5 mg/day tolvaptan with a dose increase to 15 mg/day in those with insufficient response at day 7.
Treatment Period-II was calculated by evaluating the changes in body weight between days 7 and 14. Urine samples were collected, to determine cumulative daily urine volume on days 1, 7, 8 and 14.
Safety evaluation
Safety assessment was performed throughout the study after the first administration of tolvaptan. The safety evaluation was based on the assessment of physical signs and symptoms, laboratory tests (haematology, clinical chemistry and urinalysis), vital signs (blood pressure, pulse rate and body temperature), and 12-lead electrocardiography. Blood samples to determine serum sodium concentrations were collected at baseline, at 4-8 h and at 22-24 h after dosing on days 1 and 8 (although they were not collected for patients on 7.5 mg/day, on day 8); and at 22-24 h after dosing on days 7 and 14. Blood samples were collected in sterile tubes containing heparin sodium (39 IU in 2 ml).
Statistical analyses
Analyses were performed on the full analysis set, which included all patients who received the trial drug at least once. Missing data at the final evaluation day were imputed by the last data obtained after the start of investigation (the 'last observation carried forward' method). Patients who received the trial drug at least once were included in the safety assessment.
Continuous data were presented as mean AE SD. Descriptive statistics in changes in body weight, abdominal circumference, serum sodium concentration and daily urine volume at each timepoint from baseline, and number of responders, were calculated. These analyses were conducted using the paired t-test. All statistical analyses were performed using SAS Õ software, version 9.1.3 (SAS Institute, Cary, NC, USA). A two-tailed P-value < 0.05 was considered statistically significant.
Results
A total of 71 patients were enrolled in this study, of whom 61 met the inclusion criteria. Figure 2 shows the patient disposition. Ten patients were withdrawn during the pretreatment observation period (ineligible n ¼ 3, protocol violation n ¼ 1, investigator's decision n ¼ 6). Fifty-one patients proceeded to the treatment period, of whom five were withdrawn due to adverse events (one each of malaise, increased serum potassium level, Table 1 . Baseline demographic and clinical characteristics of patients with hepatic oedemaassociated ascites refractory to conventional diuretic treatment, included in a study to evaluate efficacy and safety of 7.5 mg/day tolvaptan with a dose increase to 15 mg/day in those with insufficient response at day 7 (n ¼ 51). Figure 2 ). Patient demographics and baseline characteristics are shown in Table 1 .
The mean change in body weight from baseline in all patients (n ¼ 46) who completed Treatment Period-I was significantly reduced by day 7 (P < 0.0001; Figure 3 ). Those who responded to 7.5 mg/day tolvaptan in Treatment Period-I (7.5 mg Patients) continued to respond in Treatment Period-II, with further significant mean decreases in body weight (P < 0.0001; Figure 4 ). Among 15 mg Patients, there were no mean decreases in in body weight on days 7 or 14.
Just over half of all patients achieved a response (!1 kg decrease in body weight) at the end of Treatment Period-I ( Table 2) . Of those who responded in Treatment Period-I, 43% achieved further body-weight reductions of !1.0 kg between days 7 and 14. Of those who initially did not respond, who then received a higher dose of tolvaptan in Treatment Period-II, three of 13 (23%) achieved a body-weight reduction !1.0 kg.
In all patients, mean abdominal circumference decreased significantly from baseline after 7 days of tolvaptan 7.5 mg/day (Table 3 ). Only '7.5 mg Patients' showed a statistically significant decrease from baseline in abdominal circumference at days 7 and 14 (P < 0.0001). Urine volume was significantly increased from baseline on day 1 through day 14, for both doses (P < 0.05), except for 15 mg Patients on day 14 (Table 4 ).
In all patients and at both doses, mean serum sodium concentration increased significantly between baseline and day 7 (P ¼ 0.003; Table 5 ). In Treatment Period-II, the mean serum sodium concentration increased significantly in 15 mg Patients on day 14, but not in 7.5 mg Patients. Serum sodium values were within the normal range (135-144 mEq/l) 25,26 on day 7 in all patients in Treatment Period-I, and on day 14 at both doses in Treatment Period-II.
Adverse events were observed in 42 patients (82%) during the entire treatment period (Table 6) ; the most frequent adverse event was thirst, followed by fever, insomnia, decreased blood pressure, constipation and hepatic encephalopathy. Two patients experienced serious adverse events: one case of oesophageal varices haemorrhage on day 14; one case of hepatic encephalopathy, who stopped treatment on day 3. The association between the hepatic encephalopathy and tolvaptan could not be ruled out. 
Discussion
The present study demonstrated that just over half of the enrolled patients with hepatic oedema who had failed to respond to conventional diuretic treatment responded to 7 days' treatment with tolvaptan 7.5 mg/day. Those patients who responded to this treatment continued to achieve body weight decreases on the same dose of tolvaptan during the subsequent 7 days. In those who did not initially respond Table 3 . Abdominal circumference at baseline and after 7 days' treatment with tolvaptan 7.5 mg (Treatment Period-I) and after an additional 7 days' treatment with either 7.5 or 15 mg/day tolvaptan, in patients with hepatic oedema-associated ascites refractory to conventional diuretic treatment. A loop diuretic, such as furosemide, has superior diuretic action to other types of diuretics, although it is associated with adverse drug reactions including hyponatraemia and renal impairment. 3, 4, 27, 28 Combination therapy with tolvaptan plus a loop diuretic in the present study led to a sustained decrease in body weight during the entire treatment period, in patients who were responders in Treatment Period-I, with minimum effect on serum sodium concentration. Thus, the combination therapy of the aquaretic tolvaptan with a loop diuretic could be a novel treatment option in patients with hepatic oedema without heightened risk of electrolyte imbalance. 14 The use of tolvaptan presupposes concomitant use with other conventional diuretics in Japan. Tolvaptan increases serum sodium concentrations as a result of improvement in hyponatraemia. Although conventional diuretics, particularly loop diuretics with urinary sodium excretion, do not exert adequate diuresis in patients with hyponatraemia, tolvaptan is expected to exert its sufficient diuresis by increasing the serum sodium concentration. Thus, even when patients do not respond to conventional diuretics alone, diuretics should be administered concomitantly with tolvaptan.
The safety analysis showed that adverse events were observed in 82% of patients during the 14-day treatment period. The most commonly observed adverse event was thirst, as predicted from the pharmacological action of tolvaptan. Safety analyses suggested that the incidence of thirst was reduced over time, as a lower incidence was observed in the second 7-day period.
There were some limitations to the present study. A treatment period >14 days and a higher dose than 15 mg/day tolvaptan could be allocated to patients who do not respond to 7.5 mg/day. 22 This single-arm study was designed to evaluate efficacy and safety of tolvaptan at 7.5 mg/day for 14 days. For this purpose, the sample size was sufficient.
In conclusion, based on the current study, tolvaptan is considered to be an effective aquaretic agent, offering a novel treatment 
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